ZURICH, Switzerland, September 1, 2011 /PRNewswire/ --
Study Assessing the Safety and Efficacy of KUR-211 Expected to Report in mid 2012
Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has completed recruitment in a Phase IIb clinical trial designed to investigate KUR-211 (Viz.I-020201) in the treatment of diabetic foot ulcers.
This Phase IIb clinical trial is a randomised, multi-center, controlled, parallel group dose-finding study to evaluate the efficacy and safety of KUR-211 used as an adjunct to standard of care in patients with diabetic foot ulcers. KUR-211 is a bioactive therapy intended for topical treatment of diabetic foot ulcers, stimulating the granulation tissue formation, that aids wound closure. The study evaluates the effects of KUR-211 applied twice a week for maximum 16 weeks in addition to standard of care versus standard of care (SOC) alone.
KUR-211 consists of a modified variant of platelet-derived growth factor (PDGF) incorporated into a fibrin sealant and is applied to the wound as a foam. The innovative Kuros "TG-hook" technology enables the PDGF to be retained at the site for local exposure to migrating cells and for sustained delivery of PDGF on enzymatic cleavage of the matrix. It is believed that this novel approach may improve the frequency and speed of healing.
A total of 211 patients have been randomized and treated in over 27 centers across Europe including Russia. The primary endpoint of this study is percentage reduction in ulcer surface area after 4 weeks of treatment when compared to SOC alone. Patients are followed for 7 months following initial treatment. Kuros is expecting to report the outcome of this study around the middle of 2012.
Dr. Virginia Jamieson, Chief Medical Officer of Kuros, commented: "We are very pleased t
|SOURCE Kuros Biosurgery AG|
Copyright©2010 PR Newswire.
All rights reserved